Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of TMC114 (Darunavir) in Experienced HIV-1 Patients
NCT00115050Phase 3Completed
- Sponsor
- Tibotec
- Start
- Jun 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Tibotec. Primary endpoint: Provide early access to TMC114. Started Jun 2005; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00115050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115050.